

Acknowledgment and Consent for Disclosure of Potential Conflict(s) of Interest and Waivers
under 18 U.S.C. §208(b)(3) and 21 U.S.C. §355(n)(4)

Name of Participant: Daniel Scharfstein, Sc.D.

Committee: Vaccines and Related Biological Products Advisory Committee

Meeting Date: December 15, 2005

I acknowledge that contingent upon public disclosure of the following financial interest listed below related to: the review of the safety and efficacy of Zostavax manufactured by Merck for the treatment of zoster, I am eligible to receive waivers under 18 U.S.C. 208(b)(3) and 21 U.S.C. §355(n)(4).

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
Consulting	With a competitor	Fee is less than \$10,001 per year
Stock	With the Sponsor	Valued less than \$10,001

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of the interests the waivers are not valid.


Daniel Scharfstein, Sc.D.

11/29/05
Date